Philip Bergman, DVM, MS, PhD, DACVIM (Oncology), kicked off the 2025 Fetch Charlotte conference with his keynote address on ...

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

Skin cancer is the most common cancer in the U.S., with risks influenced by factors like sun exposure, skin type, and income.

Living in Arizona provides the opportunity for amazing outdoor recreation and year-round sunshine. Because of this year-round ...

F or patients diagnosed with stage 4 cancer, a condition often accompanied by limited treatment options and grim prognoses, ...

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

A NEW study has explored the effects of combining nivolumab, an immunotherapy drug, with hypofractionated radiotherapy in ...

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Lifelong skincare obsessive Jess Armstrong refused to settle for boring clinical products after chemotherapy left her skin ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

There are two main types of skin cancer; Non-melanoma skin cancer and melanoma. Non-melanoma skin cancer, which slowly develops in the skin's upper layers, is separated from the less common but more s ...